Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

NCT00647426 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Sorafenib + Docetaxel/Carboplatin

Sponsor

Abramson Cancer Center at Penn Medicine